<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133574</url>
  </required_header>
  <id_info>
    <org_study_id>S354.1.001</org_study_id>
    <secondary_id>2009-017008-10</secondary_id>
    <nct_id>NCT01133574</nct_id>
  </id_info>
  <brief_title>This is a Single Ascending Dose Tolerance Study</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance
      imaging (Part B)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Part A of this study is a parallel design followed in a second part by a cross-over
      design
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part A completed successfully 22 July 2010, Part B will be separate PET study
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part A)</measure>
    <time_frame>1 week after each dose level</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part B)</measure>
    <time_frame>2 weeks after each dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (AUC and Cmax) after single ascending oral dosing of max. 8 doses of SLV354 ranging from 20 to 1250 mg (Part A)</measure>
    <time_frame>1 week after each dose level</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables (EEG, Cognitive tests, Questionnaires, plasma hormones ACTH / cortisol / TSH / T3 / T4) (Part A)</measure>
    <time_frame>1 week after each dose level</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (AUC and Cmax) after single oral dosing of 2-4 doses of SLV354 chosen (Part B)</measure>
    <time_frame>2 weeks after each dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables : Cognitive tests, Questionnaires, fMRI) (Part B)</measure>
    <time_frame>2 weeks after each dose</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Cognition Disorders</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A, Parallel design Arm 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A, Parallel design Arm 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Cross-over design, Arm 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Cross-over design, Arm 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Cross-over design, Arm 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B, Cross-over design, Arm 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B, Cross-over design, Arm 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>20 mg</description>
    <arm_group_label>A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>60 mg</description>
    <arm_group_label>A2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>120 mg</description>
    <arm_group_label>A3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>250 mg</description>
    <arm_group_label>A4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>500 mg</description>
    <arm_group_label>A5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>750 mg</description>
    <arm_group_label>A6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>1000 mg</description>
    <arm_group_label>A7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>1250 mg</description>
    <arm_group_label>A8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>placebo</description>
    <arm_group_label>A9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>low dose group 1</description>
    <arm_group_label>B1-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>high dose group 1</description>
    <arm_group_label>B1-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>low dose group 2</description>
    <arm_group_label>B2-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLV354 capsules</intervention_name>
    <description>high dose group 2</description>
    <arm_group_label>B2-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>placebo</description>
    <arm_group_label>B3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  BMI 18.0 to 28.0 kg/m2,

          -  systolic blood pressure 90-140 mmHg,

          -  diastolic blood pressure 50-90 mmHg,

          -  heart rate 50 100 beats/min (all inclusive),

          -  clinically normal safety ECG and laboratory results

        Exclusion Criteria

          -  relevant disease,

          -  treated with SLV354 before
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Rendenbach-Mueller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 62002</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>SLV354</keyword>
  <keyword>Phase I</keyword>
  <keyword>SRDT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

